19 December 2023
EMBL Hamburg, Johannes Gutenberg University Mainz, Postnova Analytics GmbH, and BioNTech SE have developed a new method to quantitatively investigate sizes of nanoparticles containing mRNA. It may become an important part of regular characterisation of mRNA nanomedicines in the future.
14 December 2023
Former EMBL staff scientist founds a start-up – DenovAI – for broader, faster and cheaper antibody discovery using advanced machine learning and computational biophysics.
27 November 2023
An interdisciplinary collaboration between Hamburg scientists has yielded new insights into the structure and function of a heat-resistant enzyme from an exotic microbe. In this interview, EMBL Hamburg’s Matthias Wilmanns and TUHH’s Garo Antranikian discuss how their collaboration developed and…
15 November 2023
Sara Fahs, who did her PhD from EMBL Heidelberg and is one of the newest members of the EMBL alumni association board, writes about key insights from her journey in science and her work on medicinal chemistry, during a career spanning academia and industry.
2 October 2023
Pioneers of the mRNA nanomedicines technology receive 2023 Nobel Prize in Physiology or medicine. EMBL is pleased to have supported the development of the application of the mRNA nanomedicine technology through our long-standing collaboration with BioNTech, Johannes Gutenberg University Mainz and…
21 September 2023
Announcements, Lab Matters
David Hulcoop discusses how his experience bridging organisational cultures will help address critical challenges in drug discovery and target selection at Open Targets.
28 July 2023
EMBL organised a five-day summer school to help PhD students and postdocs learn more about research and development (R&D) related industry career roles.
14 July 2023
EMBL researchers use a new cell sorting technology to gain new insights into cellular function in health and disease, as well as for other innovative applications.
5 July 2023
Coming from a pharmaceutical industry background, David Hulcoop is set to take over as Executive Director of the public-private partnership Open Targets.
29 June 2023
New framework to improve the FAIRness of clinical and molecular datasets
27 June 2023
Science, Technology and innovation
HoloFood, the first consistent collection of multiomic data about chicken and salmon gut microbiomes, set to enable the development of better animal feeds.
4 May 2023
Vizgen, the life science company dedicated to improving human health by visualising single-cell spatial genomics information, has joined EMBL’s Corporate Partnership Programme.
18 April 2023
Nikon Europe has intensified its engagement with EMBL's Corporate Partnership Programme to support young scientists.
13 March 2023
An annual Corporate Partnership Programme meeting provided a forum for EMBL researchers and industry representatives to discuss mobile labs, planetary biology, and other areas of common interest.
10 February 2022
Open Targets, a consortium focused on drug target identification, prioritisation, and validation, announced today that Pfizer has joined as a partner.
21 January 2022
EMBL researchers, in collaboration with BD Biosciences, have demonstrated a new technology that allows rapid image-based sorting of cells. The new technology represents a major upgrade to flow cytometry and has applications in diverse life science fields.
7 December 2021
RNA vaccines, such as the ones for COVID-19, represent a new approach in vaccine technology. Cy Jeffries, faculty staff scientist at EMBL Hamburg, explains the clever technology behind RNA vaccines, and how structural biology contributes to its development. EMBL Hamburg collaborated on several…
10 November 2021
Independent impact review finds EMBL experimental services are ‘critical’ for research and endorses EMBL as a world-class service provider for academia and industry.
21 July 2021
Researchers establish a framework for identifying new drugs capable of exploiting a cell’s own machinery.
5 June 2021
EMBL’s EU Green Week event showcased various ways molecular biology research can help solve environmental challenges.
6 April 2021
Scientists have determined the structure of Glycine Transporter 1. The finding could open new avenues for developing therapeutics for psychiatric disorders
1 December 2020
Biotechnology company BioNTech and Johannes Gutenberg University Mainz conduct collaborative research with EMBL scientists at the beamline P12 in Hamburg
15 June 2020
The European Molecular Biology Laboratory has secured 6.8 million Euros funding from the European Commission to launch a unique training programme. The ARISE Programme will train and develop Europe’s next generation leadership for research infrastructures in the life sciences.
28 June 2019
EIPOD4 will prepare researchers for the increasing interdisciplinarity of scientific career paths
12 April 2019
Building bonds between academia and industry
17 January 2019
Joining forces to advance training in biomedical research and therapy
3 December 2018
EMBL-EBI industry case study: Biocatalysts
28 November 2018
EMBL postdocs discover industry-led research opportunities at the Corporate Summer School
30 October 2018
Pharmaceutical company Sanofi strengthens drug targets discovery collaboration Open Targets
20 September 2018
EMBL and Promega collaborate to train young scientists
16 August 2018
The ATTRACT initiative, of which EMBL is a partner, has launched an open call for seed funding
11 June 2018
Roche and EMBL join forces
24 May 2018
EMBL-EBI PhD student launches start-up focusing on epigenetics and wellbeing
4 May 2018
New partner strengthens drug discovery collaboration
7 March 2018
New EMBL spinoff company Velabs Therapeutics aims to speed up discovery of therapeutic antibodies
21 February 2018
Joining forces for single-cell research
4 December 2017
Takeda joins pioneering public-private drug discover collaboration Open Targets
20 November 2017
EMBL and HeidelbergCement sign Memorandum of Understanding
15 June 2017
Exploring the potential of user experience for life sciences through industry workshops
8 May 2017
Accelerating researchers’ access to next-generation light-sheet microscopy
6 March 2017
EMBL alumnus Joep Muijrers talks about making the transition from science into business
26 September 2016
Side-effects of leukaemia drug explained, reveal possibility of repurposing to treat other diseases
30 August 2016
Alumnus and entrepreneur Marc Zabeau speaks at inaugural Life Science Funders and Foundations event
23 May 2016
Abel Ureta-Vidal and Louise Modis join colleagues and peers at gathering of UK-based alumni
8 February 2016
Pioneering target validation collaboration expands to accelerate drug discovery research.
4 February 2016
Protein screens developed at EMBL Hamburg now commercially available
8 December 2015
Identifying evidence-based relationships between drug targets and diseases.
13 July 2015
EI3POD: flagship interdisciplinary postdoc programme opens its doors to academia and industry.
2 July 2015
Industrial partners and BioStruct-X facility members gather for Workshop at EMBL Hamburg.
29 April 2015
Career insights from Riccardo Cortese, whose start-up is developing an Ebola vaccine candidate.
29 April 2015
Alumni in senior positions in industry share career challenges, highlights and EMBL’s continuing role.
25 March 2015
EMBL’s corporate partners zoom in on big data and bioimaging.
24 November 2014
Life Science Nord event reveals how pharmaceutical companies use synchrotrons for their research.
1 July 2014
As the Lab turns 40, staff and alumni share 40 things that make EMBL, EMBL
1 July 2014
Two EMBL alumni, each developing community-led tools to support life science research
25 June 2014
A new EMBL-EBI biomedical initiative works to determine the best target proteins for new drugs.
22 January 2007
The European Commission has awarded 3.7 Million Euro under the European Union Framework 6 Programme over the next four years to a new Marie Curie Research Training Network, coordinated by Dr. Andreas Ladurner at the European Molecular Biology Laboratory (EMBL). The long molecules of DNA that carry…
9 August 2006
Today EMBL scientists, EMBL’s commercial affiliate, EMBL Enterprise Management Technology Transfer GmbH (EMBLEM) and EMBL’s venture vehicle, EMBL Ventures GmbH, announce the foundation of Elara Pharmaceuticals GmbH, a start-up company that will translate basic research findings into new…
No matching posts found